重庆华森制药两药品获再注册批准，短期业绩影响不大

Core Viewpoint - Chongqing Huasen Pharmaceutical Co., Ltd. has received approval from the Chongqing Municipal Drug Administration for the re-registration of one chemical raw material (Dipotassium Glycyrrhizinate) and one drug (Sodium Ferulate Injection) [1] Group 1: Product Approvals - The re-registration approval includes a notification for the chemical raw material Dipotassium Glycyrrhizinate, which is used for the production of Glycyrrhizinate Injection [1] - The Sodium Ferulate Injection is indicated for the auxiliary treatment of ischemic cardiovascular and cerebrovascular diseases [1] Group 2: Impact on Operations - The re-registration approval will ensure the normal production and sales of the related drugs [1] - The company will strictly control product quality [1] - However, there is no significant short-term impact on the company's operating performance [1]